| |
Protocol Number:
09-C-0103
- Title:
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
- Number:
09-C-0103
- Summary:
Background:
- The Lung Cancer section of the National Cancer Institute's Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer.
Objectives:
- To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer.
- To establish a repository of genetic information for future studies of these differences and their relation to lung cancer.
Eligibility:
- Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute.
Design:
- After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential.
- Approximately half a tablespoon of blood will be drawn.
- Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study
-Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.
- Sponsoring Institute:
-
National Cancer Institute (NCI)
- Recruitment Detail
- Type:
Participants currently recruited/enrolled
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
Children
- Eligibility Criteria:
INCLUSION CRITERIA:
1. Patients 18 years of age and older are eligible.
2. Histologic diagnosis of primary lung carcinoma. For non small cell lung cancer, patients can be stage I to IV, and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy). For small cell lung cancer, patients can be limited or extensive stage and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy).
3. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol.
4. Patients with a current diagnosis of or a prior history of other cancers may be included onto this protocol.
5. Patients may have either normal organ function or impaired organ function.
EXCLUSION CRITERIA:
1. Children will not be eligible.
- Special Instructions:
Currently Not Provided
- Keywords:
-
NSCLC
-
Genotype
-
SCLC
- Recruitment Keyword(s):
-
Lung Cancer
-
Non-Small Cell Lung Cancer
-
NSCLC
-
Small Cell Lung Cancer
-
SCLC
- Condition(s):
-
Non Small-cell Lung Cancer
-
Small-cell Lung Cancer
- Investigational Drug(s):
- None
- Investigational Device(s):
- None
- Intervention(s):
- None
- Supporting Site:
- National Cancer Institute
- Contact(s):
-
NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
Phone: 1-888-NCI-1937
Fax: Not Listed
Electronic Address: ncicssc@mail.nih.gov
- Citation(s):
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96.
-
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60.
-
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.
If you have:
Search The Studies | Help | Questions |
Clinical Center Home | NIH Home
 National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 11/25/2009
|
|
